QuantaMatrix’s direct Rapid Antimicrobial Susceptibility Testing system (dRAST™) improves optimal prescription of antibiotics by two days compared to conventional methods – thanks to gram-negative and gram-positive sepsis-causing bacteria panels Follows successful adoption of dRAST solution in routine clinical use in clinical laboratories in Europe and Asia

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported that, following positive results in the lead-in phase of the clinical phase Ib/II trial TRIFOUR, the first triple-negative breast cancer (TNBC) patient has initiated treatment with the IL1RAP-binding antibody nadunolimab (CAN04) and chemotherapy in the phase II randomized part of the trial. Up to 98 patients may […]

Building on a 25+ year partnership, the companies will each provide one of the largest hemostasis testing system and reagent portfolios to laboratories. Under the multi-year agreement, both companies will individually distribute their combined portfolio of hemostasis instruments and reagents worldwide under their respective own brands.

Making clinical proteomics 100x more robust and 10x faster   Evosep aims to improve quality of life and patient care by radically innovating protein based clinical diagnostics. We will make sample preparation and separation for MS analysis 10 times faster and 100 times more robust in order to enable truly large cohort studies and provide […]